REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Post-Surgery Recovery

Recovery & Healingintermediate

88

synergy

88
Peptides

3

Avg Daily mcg

7,000

Level

intermediate

Added

May 17, 2026

Overview

The Post-Surgery Recovery stack is designed for accelerated healing following surgical procedures, combining tissue-repair peptides with immune support to address the dual challenges of wound healing and infection prevention. BPC-157 at standard dosing promotes angiogenesis and growth factor expression at surgical sites, while TB-500 is used at a higher loading dose (5000mcg) to maximize its systemic anti-inflammatory and tissue-migration effects during the critical early post-operative window. Thymosin Alpha-1 (Ta1) is the immune-support cornerstone of this stack. It is a 28-amino-acid peptide originally isolated from thymic tissue that enhances T-cell maturation, dendritic cell activation, and natural killer cell function. Ta1 is approved in over 35 countries under the brand name Zadaxin for hepatitis B/C and as an immune adjuvant. In the post-surgical context, it helps prevent opportunistic infections during the immunosuppressive period following anesthesia and surgical trauma, while also modulating inflammation to prevent excessive scarring. The synergy here is particularly elegant: BPC-157 and TB-500 handle the structural repair — new blood vessel formation, cellular migration, extracellular matrix deposition, and anti-inflammatory signaling — while Thymosin Alpha-1 ensures the immune system remains vigilant against post-surgical infections without triggering excessive inflammatory responses that could impair healing. This combination addresses the clinical reality that surgical recovery requires both tissue repair and immune competence, and that these processes must be balanced rather than maximized independently. This stack should only be used under physician supervision, ideally beginning 24-48 hours after surgery once initial hemostasis is established.

Dosing Protocol

BPC-157

Twice per day· subcutaneous

250 mcg

per dose

TB-500

2x/week· subcutaneous

5,000 mcg

per dose

Thymosin Alpha-1

Every day· subcutaneous

1,500 mcg

per dose

Goals & Evidence

Surgical recoveryWound healingImmune supportTissue repairScar reduction
Evidence tier:Human Data

Warnings

  • Must be supervised by prescribing physician. BPC-157 and TB-500 are Cat 2. Thymosin Alpha-1 is Cat 1 (approved in 35+ countries).

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.